Hints and tips:
Related Special Reports
...Martin Holst Lange, executive vice-president of development at Novo Nordisk, said preventing obesity would be the “holy grail”....
...“We have a very nice palette across the range of efficacy, safety and scalability and that allows us to be in the driver’s seat,” said Martin Holst Lange, Novo Nordisk’s vice-president of development....
...Martin Holst Lange, head of development at Novo Nordisk, said the potential of the ultrasound technology was “compelling”....
...Katie Martin I’m with Ethan on this . . . Robert Armstrong Agree. Katie Martin I think....
...Martin Holst Lange, executive vice-president for development at Novo, said that until now there had been no approved weight management drug that also reduced the risk of heart attack or stroke....
...and Lockheed Martin....
...Nvidia took up all the oxygen last week, but don’t sleep on Eli Lilly. Strong earnings fuelled by weight-loss drugs have pushed the stock up 32 per cent this year....
...Investing: There may be some truth to fund managers’ grumbles that passive investing meaningfully alters the markets, writes Katie Martin....
...Martin Holst Lange, executive vice-president of development at Novo Nordisk, said new data showed in more detail how the drug was “incredibly powerful” in tackling cardiovascular risk....
...But Lilly of the IfG said anyone with weekly auto-delete would have to upload any relevant messages to a centralised system every six days....
...The US Food and Drug Administration delayed an approval decision on Eli Lilly’s breakthrough Alzheimer’s disease drug, which was expected to be approved this month....
...The initial result was “out of this world”, says Martin Lange, executive vice-president of development for Novo Nordisk....
...US aerospace and defence group Lockheed Martin forecast a larger than expected increase in 2024. The World of Work US banks are toughening up requests for employees to return to the office....
...Passive problem Research bolsters the view that passive investment strategies are undermining the efficient markets hypothesis, the FT’s Katie Martin writes....
...Tobey is adviser to many Fortune 500 companies including CVS, 3M and Eli Lilly, and regularly speaks to a range of organisations on the risks and benefits of AI....
...Martin Vanderploeg, non-exec chair, Workiva To utilise genAI . . ....
...Lockheed Martin is among the non-financial companies reporting....
...Q4, Thomson Reuters Q3, Toyota Q2 Thursday UK, Bank of England announces its interest rate decision Results: Apple Q4, Bombardier Q3, BT Group H1, Cloudflare Q3, Coinbase Global Q3, Dropbox Q3, Eli Lilly...
...Lockheed Martin, Johnson & Johnson and Albertsons also report quarterly earnings ahead of the market opening. Air carrier United Airlines will report after the bell....
...Unlike BioArctic, Lilly targeted the solid form of amyloid beta, the plaques....
...Rival Eli Lilly has won approval for its own obesity drug, which could be more effective and currently has a lower list price....
...Martin says that discovery phases that would usually take around four years have taken Generate 16 months....
...Critics have also slammed industry leaders Eli Lilly and Biogen for charging excessive prices for treatments for common diseases such as diabetes and Alzheimer’s....
...This included a fake Eli Lilly account that said the drugmaker was giving away free insulin....
International Edition